FORENDO PHARMA LTD has a total of 50 patent applications. Its first patent ever was published in 2008. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are UMECRINE AB, JENAPHARM GMBH AND CO KG and NEURMEDIX INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | United States | 7 | |
#3 | WIPO (World Intellectual Property Organization) | 7 | |
#4 | China | 6 | |
#5 | Argentina | 3 | |
#6 | Taiwan | 3 | |
#7 | Australia | 2 | |
#8 | Brazil | 2 | |
#9 | Canada | 2 | |
#10 | Israel | 2 | |
#11 | Republic of Korea | 2 | |
#12 | Singapore | 2 | |
#13 | Chile | 1 | |
#14 | Hong Kong | 1 | |
#15 | Morocco | 1 | |
#16 | Mexico | 1 | |
#17 | Tunisia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Koskimies Pasi | 43 |
#2 | Lammintausta Risto | 31 |
#3 | Eloranta Maire | 27 |
#4 | Hirvelä Leena | 26 |
#5 | Kangas Lauri | 23 |
#6 | Unkila Mikko | 23 |
#7 | Hakola Marjo | 20 |
#8 | Hirvela Leena | 13 |
#9 | Stjernschantz Camilla | 12 |
#10 | Linnanen Tero | 12 |
Publication | Filing date | Title |
---|---|---|
WO2020115371A1 | Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 | |
WO2018224736A2 | 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases | |
CN107207562A | The prodrug of 17 beta hsd 1 inhibitors | |
WO2016102776A1 | Prodrugs of 17.beta.-hsd1 -inhibitors | |
CN105518016A | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 beta-hydroxysteroid dehydrogenase, type 1 | |
WO2014207310A1 | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase | |
CN105518017A | Therapeutically active estratrienthiazole derivatives as inhibitors of 17beta-hydroxy-steroid dehydrogenase, type 1 | |
EP2518039A1 | Method for the preparation of therapeutically valuable triphenylbutene derivatives |